A substance being studied in the treatment of some types of cancer. Tremelimumab binds to a protein called CTLA-4, which is found on the surface of T cells (a type of white blood cell). It may block CTLA-4 and help the immune system kill cancer cells. Tremelimumab is a type of monoclonal antibody and a type of immunomodulatory agent.